Home Cart Sign in  
Chemical Structure| 76824-35-6 Chemical Structure| 76824-35-6

Structure of Famotidine
CAS No.: 76824-35-6

Chemical Structure| 76824-35-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Famotidine is antagonist of histamine H2–receptor with IC50 of 0.6 mM that used to treat heartburn and other digestive conditions.

Synonyms: MK-208; YM-11170; Famotidine, Famotidine Hydrochloride, MK-208, Pepcid, YM-11170, YM11170, YM 11170, MK 208, MK208

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Famotidine

CAS No. :76824-35-6
Formula : C8H15N7O2S3
M.W : 337.44
SMILES Code : N=C(NS(=O)(N)=O)CCSCC1=CSC(NC(N)=N)=N1
Synonyms :
MK-208; YM-11170; Famotidine, Famotidine Hydrochloride, MK-208, Pepcid, YM-11170, YM11170, YM 11170, MK 208, MK208
MDL No. :MFCD00079297

Safety of Famotidine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P305+P351+P338

Related Pathways of Famotidine

GPCR

Isoform Comparison

Biological Activity

Target
  • H2 receptor

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 50 µM 12 hours Pretreatment of these cells with famotidine reduced TLR3 mRNA levels, but did not affect TLR7 expression. J Biol Chem. 2021 Aug;297(2):100925.
Caco2 cells 50 µM 12 hours Famotidine treatment inhibits histamine-induced expression of Toll-like receptor 3 (TLR3) in SARS-CoV-2 infected cells and can reduce TLR3-dependent signaling processes that culminate in activation of IRF3 and the NF-κB pathway, subsequently controlling antiviral and inflammatory responses. J Biol Chem. 2021 Aug;297(2):100925.
Mouse primary peritoneal macrophages 0 to 30 µM 16 hours To evaluate the inhibitory effect of famotidine on LPS-induced TNF and IL-6 release, results showed that famotidine did not significantly inhibit LPS-induced TNF and IL-6 release in mouse primary peritoneal macrophages. Mol Med. 2022 May 16;28(1):57.
RAW 264.7 cells 0 to 30 µM 16 hours To evaluate the inhibitory effect of famotidine on LPS-induced TNF and IL-6 release, results showed that famotidine did not significantly inhibit LPS-induced TNF and IL-6 release in RAW 264.7 cells. Mol Med. 2022 May 16;28(1):57.
Human lung A549 cells up to 200 µM 72 hours To assess the inhibitory effect of famotidine on SARS-CoV-2 replication in human lung cells, results showed no significant antiviral activity. Sci Rep. 2021 Mar 8;11(1):5433.
Vero E6 cells up to 200 µM 72 hours To evaluate the inhibitory effect of famotidine on SARS-CoV-2 replication, results showed no significant antiviral activity at concentrations up to 200 µM. Sci Rep. 2021 Mar 8;11(1):5433.
Human lung A549 cells 0.01–200 µM 72 hours Test the inhibitory effect of ML188 on SARS-CoV-2 replication, results showed no inhibition Sci Rep. 2021 Mar 8;11(1):5433
Vero E6 cells 0.01–200 µM 72 hours Test the inhibitory effect of ML188 on SARS-CoV-2 replication, results showed no inhibition Sci Rep. 2021 Mar 8;11(1):5433

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice LPS-induced cytokine storm model Intraperitoneal injection (IP) 0.4 or 4 mg/kg Single injection or twice daily for 3 days To evaluate the inhibitory effect of famotidine on LPS-induced cytokine storm, results showed that famotidine significantly reduced serum and splenic TNF and IL-6 levels and improved survival rate. Mol Med. 2022 May 16;28(1):57.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00141960 Gastroesophageal Reflux PHASE2|PHASE3 COMPLETED - Hokkaido region, Japan|Kanto r... More >>egion, Japan|Kinki region, Japan|Kyushu region, Japan|Shikoku region, Japan|Tohoku region, Japan|Tokai region, Japan Less <<
NCT01079052 Healthy COMPLETED 2025-12-07 Ranbaxy Clinical Pharmacology ... More >>Unit, Ranbaxy Laboratories Limited, Noida, Uttar Pradesh, India Less <<
NCT04389567 COVID-19 COMPLETED 2020-05-25 Cold Spring Harbor Laboratory,... More >> Cold Spring Harbor, New York, 11724, United States Less <<
NCT01079065 Healthy COMPLETED 2025-12-07 Ranbaxy Clinical Pharmacology ... More >>Unit, Ranbaxy Laboratories Limited, Noida, Uttar Pradesh, India Less <<
NCT01937078 Dyskinesia PHASE2 COMPLETED 2025-03-14 Toronto Western Hospital, Toro... More >>nto, Ontario, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.96mL

0.59mL

0.30mL

14.82mL

2.96mL

1.48mL

29.63mL

5.93mL

2.96mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories